The product infliximab for injection, licensed by Kexing Biopharm, has recently experienced a wave of encouraging news regarding its international commercialization.

Kexing Biopharm's licensed products infliximab and bevacizumab were officially notified of their qualification for site GMP inspections in Egypt after the completion of site GMP audits by the Egyptian Drug Authority (EDA) in September last year.

Unlocking the secrets of biology and harnessing its power to benefit humanity has always been at the forefront of scientific exploration. One remarkable breakthrough in this field is the discovery and utilization of recombinant proteins.

When it comes to advancements in medicine, we often think of groundbreaking discoveries and innovative treatments that have transformed the way we approach healthcare. One such breakthrough has been the rise of recombinant protein drugs, a game-changer in the world of pharmaceuticals.

Ever wondered about the marvels of modern medicine? Human erythropoietin injection, a groundbreaking treatment, is revolutionizing healthcare.

On the morning of January 3, Kexing Biopharm signed an international commercialization cooperation agreement on Eribulin Mesylate Injection, securing exclusive commercialization licensing and supply of the product from Xiling Lab Co., Ltd. in 36 countries.

iological medicines have transformed the landscape of healthcare, offering innovative solutions for various diseases and conditions. These complex therapies are created from biological sources and require meticulous attention at every stage of their production.

In recent years, the landscape of the global biotechnology and pharmaceutical industries has undergone a significant transformation, with China emerging as a formidable player in the export of biological products.